LIST OF FIGURES

Figure No	Title	Page No.
2.1	Barriers to brain delivery	9
2.2	Efflux transporters at Blood Brain Barrier	10
2.3	Transport routes across the blood–brain barrier (BBB)	14
2.4	Techniques to characterize nanoparticles	23
2.5	Schematic representation of the transferrin receptor	26
2.6	Structure of human transferrin	27
2.7	TfR internalisation upon binding of Tf to its receptor	28
2.8	Anatomy of nose: cross sectional sketch illustrating (A) the vestibular, (B) the respiratory, and (C) the olfactory region	32
2.9	Types of glioma tumors	34
3.1	UV spectrophotometric scan of Etoposide in Acetonitrile	55
3.2	Regressed calibration curve for estimation of Etoposide	56
3.3	HPLC Chromatogram for Temozolomide	59
3.4	Regressed calibration curve for estimation of Temozolomide	60
3.5	Fluorimetry curve for λemission for 6-coumarin	62
3.6	Regressed calibration curve for estimation of 6-coumarin	63
3.7	Regressed calibration curve for determination of residual PVA	65
3.8	Regressed calibration curve of Transferrin by BCA method	68
4.1	Schematic representation of the nanoprecipitation process	79
4.2	Contour plot for particle size of PLGA-ETP-NP	86
4.3	Contour plot for drug entrapment efficiency of PLGA-ETP-NP	88
4.4	Contour plot for particle size of PLGA-TMZ-NP	89
4.5	Contour plot for drug entrapment efficiency of PLGA-TMZ-NP	91
4.6	Schematic diagram of conjugation of transferrin to nanoparticle surface	94
4.7	Influence of the concentration of the activating agent SR-4GL on Tf density at the surface of PLGA-ETP-NP	106
4.8	Influence of the concentration of the SR-4GL on the particle size of PLGA-ETP-NP	107
4.9	Influence of the concentration of the activating agent SR-4GL on Tf density at the surface of PLGA-TMZ-NP	107
4.10	Influence of the concentration of the activating agent SR-4GL on the particle size of PLGA-TMZ-NP	108
4.11	Influence of amount of Transferrin taken for conjugation on surface Tf density (μg/mg) of PLGA-ETP-NP	109

4.12	Influence of amount of Transferrin taken for conjugation on particle size of PLGA-ETP-NP	110
4.13	Influence of amount of Transferrin taken for conjugation on surface Tf density (μg/mg) of PLGA-TMZ-NP	110
4.14	Influence of amount of Transferrin taken for conjugation on particle size of PLGA-TMZ-NP	111
4.15	^{1}H-NMR of Tf -PLGA-ETP-NP	112
4.16	^{1}H-NMR of Tf -PLGA-TMZ-NP	112
5.1	Particle size distribution plots of Etoposide loaded PLGA nanoparticles, before and after Tf conjugation	122
5.2	Zeta potential plots of Etoposide loaded PLGA nanoparticles, before and after Tf conjugation	123
5.3	Particle size distribution plots of Temozolomide loaded PLGA nanoparticles, before and after Tf conjugation	124
5.4	Zeta potential plots of Temozolomide loaded PLGA nanoparticles, before and after Tf conjugation	124
5.5	In-vitro release of etoposide from etoposide loaded PLGA NPs before and after conjugation with Tf	125
5.6	In-vitro release of temozolomide loaded PLGA nanoparticles before and after conjugation with Tf	126
5.7	Morphology of Etoposide nanoparticles using TEM	127
5.8	Morphology of Temozolomide nanoparticles using TEM	127
5.9	DSC thermograms for Etoposide	128
5.10	DSC thermograms for Temozolomide	130
6.1	Stability profiles-PLGA-ETP-NP (a) particle size (b) zeta potential and (c) drug content Vs time in months	140
6.2	Stability profiles-Tf-PLGA-ETP-NP (a) particle size (b) zeta potential and (c) drug content Vs time in months	141
6.3	Stability profiles- PLGA-TMZ-NP (a) particle size (b) zeta potential and (c) drug content Vs time in months	144
6.4	Stability profiles- Tf-PLGA-TMZ-NP (a) particle size (b) zeta potential and (c) drug content Vs time in months	145
6.5	Comparative release profile of Etoposide nanoparticles after 6M at 5°C ± 3°C	147
6.6	Comparative release profile of Temozolomide nanoparticles after 6M at 5°C ± 3°C	147
7.1	Influence of Incubation time on the Cellular Uptake Efficiency of Nanoparticles	156
7.2	Influence of Concentration on the Cellular Uptake Efficiency of Nanoparticles	157

7.3	Competitive Cellular Uptake Efficiency at 100μg/ml	158
7.4	Intracellular uptake of 6-coumarin loaded PLGA-NP and Tf-PLGA-NP formulations after different time points	159
7.5	Cell viability of Etoposide and Etoposide nanoparticles at 24hrs	163
7.6	Cell viability of Etoposide and Etoposide Nanoparticles at 48 hrs	163
7.7	Cell viability of Etoposide and Etoposide Nanoparticles at 72 hrs	164
7.8	Cell viability of Temozolomide Solution	166
7.9	Cell viability of Temozolomide and Temozolomide Nanoparticles at 24 hrs	166
7.10	Cell viability of Temozolomide and Temozolomide Nanoparticles at 48 hrs	167
7.11	Cell viability of Temozolomide and Temozolomide Nanoparticles at 72 hrs	167
8.1	Effect of Variable molar concentration of DTPA on radiolabeled 99mTc complex of Etoposide formulations	181
8.2	Effect of Variable molar concentration of DTPA on radiolabeled 99mTc complex of Temozolomide formulations	185
9.1	Blood concentration Vs. Time (hr) plot for ^{99m}TC - Etoposide formulations	193
9.2	Brain concentration Vs. Time (hr) plot for ^{99m}TC - Etoposide formulations	196
9.3	Gamma Scintigraphy image of mice after 2hrs of intravenous injection of ETPS (A), PLGA-ETP-NP (B) and Tf-PLGA-ETP-NP (C)	199
9.4	Blood concentration Vs. Time (hr) plot for ^{99m}Tc Temozolomide formulations	202
9.5	Brain concentration Vs. Time (hr) plot for ^{99m}Tc Temozolomide formulations	205
9.6	Gamma Scintigraphy image of mice after 2hrs of intravenous injection of TMZS (A), PLGA-TMZ-NP (B) and Tf-PLGA-TMZ-NP (C)	207